Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd-R Burmester

Showing results (111-120 of 293) with videos related to

Pageof 30
Sort By:
Arthritis Research & Therapy|March 13, 2012
The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expressionDaniela Frölich, Daniela Blassfeld, Karin Reiter, et al.
Journal of Periodontology|March 1, 2016
Increased Periodontal Attachment Loss in Patients With Systemic SclerosisNicole Pischon, Daniela Hoedke, Sven Kurth, et al.
Rheumatology (Oxford, England)|September 11, 2021
Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritisGerd R Burmester, Vivian P Bykerk, Maya H Buch, et al.
RMD Open|September 1, 2025
To optimise the diagnostic process of rheumatic diseases affecting the hands using fluorescence optical imaging (FOI)Nele Stumper, Jörn Berger, Jens Klotsche, et al.
RMD Open|July 3, 2021
Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study-a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trialClaudia Kedor, Jacqueline Detert, Rolf Rau, et al.
RMD Open|May 28, 2021
Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposureGerd R Burmester, Peter Nash, Bruce E Sands, et al.
Rheumatology and Therapy|April 29, 2024
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical TrialsGerd R Burmester, Jayne Stigler, Andrea Rubbert-Roth, et al.
Advances in Therapy|January 3, 2024
Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled TrialsEduardo Mysler, Gerd R Burmester, Christopher D Saffore, et al.
EULAR Rheumatology Open|June 29, 2026
Efficacy, safety, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab intravenously administered to adults with active rheumatoid arthritis and an inadequate response to methotrexate: a phase 3, randomised studyHiroaki Matsuno, Ernest Choy, Paul Emery, et al.
Arthritis and Rheumatism|September 12, 2013
Indocyanine green-enhanced fluorescence optical imaging in patients with early and very early arthritis: a comparative study with magnetic resonance imagingStephanie G Werner, Hans-Eckhard Langer, Peter Schott, et al.
Pageof 30

Showing results (111-120 of 293) with videos related to

Sort By:
Pageof 30
Arthritis Research & Therapy|March 13, 2012
The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expressionDaniela Frölich, Daniela Blassfeld, Karin Reiter, et al.
Journal of Periodontology|March 1, 2016
Increased Periodontal Attachment Loss in Patients With Systemic SclerosisNicole Pischon, Daniela Hoedke, Sven Kurth, et al.
Rheumatology (Oxford, England)|September 11, 2021
Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritisGerd R Burmester, Vivian P Bykerk, Maya H Buch, et al.
RMD Open|September 1, 2025
To optimise the diagnostic process of rheumatic diseases affecting the hands using fluorescence optical imaging (FOI)Nele Stumper, Jörn Berger, Jens Klotsche, et al.
RMD Open|July 3, 2021
Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study-a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trialClaudia Kedor, Jacqueline Detert, Rolf Rau, et al.
RMD Open|May 28, 2021
Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposureGerd R Burmester, Peter Nash, Bruce E Sands, et al.
Rheumatology and Therapy|April 29, 2024
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical TrialsGerd R Burmester, Jayne Stigler, Andrea Rubbert-Roth, et al.
Advances in Therapy|January 3, 2024
Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled TrialsEduardo Mysler, Gerd R Burmester, Christopher D Saffore, et al.
EULAR Rheumatology Open|June 29, 2026
Efficacy, safety, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab intravenously administered to adults with active rheumatoid arthritis and an inadequate response to methotrexate: a phase 3, randomised studyHiroaki Matsuno, Ernest Choy, Paul Emery, et al.
Arthritis and Rheumatism|September 12, 2013
Indocyanine green-enhanced fluorescence optical imaging in patients with early and very early arthritis: a comparative study with magnetic resonance imagingStephanie G Werner, Hans-Eckhard Langer, Peter Schott, et al.
Pageof 30